While targeted therapies and immune checkpoint inhibitors such as anti–PD-1/PD-L1 antibodies have shown promise in certain glioma subsets, their clinical efficacy remains inconsistent, underscoring the urgent need for novel prognostic biomarkers and therapeutic targets. Here, PDCD1 is linked to glioma.